Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Abvc Biopharma (ABVC) Cost of Revenue (2018 - 2024)

Historic Cost of Revenue for Abvc Biopharma (ABVC) over the last 7 years, with Q3 2024 value amounting to $296.0.

  • Abvc Biopharma's Cost of Revenue fell 9900.05% to $296.0 in Q3 2024 from the same period last year, while for Sep 2025 it was $486.0, marking a year-over-year decrease of 9965.28%. This contributed to the annual value of $763.0 for FY2024, which is 9974.74% down from last year.
  • Per Abvc Biopharma's latest filing, its Cost of Revenue stood at $296.0 for Q3 2024, which was down 9900.05% from $190.0 recorded in Q2 2024.
  • Abvc Biopharma's Cost of Revenue's 5-year high stood at $265411.0 during Q4 2022, with a 5-year trough of $190.0 in Q2 2024.
  • Over the past 5 years, Abvc Biopharma's median Cost of Revenue value was $3959.0 (recorded in 2020), while the average stood at $32264.1.
  • As far as peak fluctuations go, Abvc Biopharma's Cost of Revenue skyrocketed by 937219.84% in 2022, and later plummeted by 9973.97% in 2024.
  • Quarter analysis of 5 years shows Abvc Biopharma's Cost of Revenue stood at $1902.0 in 2020, then soared by 47.32% to $2802.0 in 2021, then soared by 9372.2% to $265411.0 in 2022, then plummeted by 47.55% to $139206.0 in 2023, then plummeted by 99.79% to $296.0 in 2024.
  • Its Cost of Revenue stands at $296.0 for Q3 2024, versus $190.0 for Q2 2024 and $277.0 for Q1 2024.